Colorectal cancers (CRC) are the second most leading cause of cancer deaths worldwide (2020). To aid in the early diagnosis and direct treatment trajectories for CRC patients, molecular/genetic profiling is invaluable. Our new CRC circulating tumor DNA (ctDNA) reference panel is made with a unique blend of engineered cell lines with clinically relevant mutations specific to CRCs. This panel mimics ctDNA and can be used as a reference material to validate NGS and other molecular biology workflows for the detection of key actionable mutations in genes like AKT1, APC, BRAF, KRAS, PIK3CA and TP53 (please refer table below to see full list of genes). The allelic frequencies for the variants in the panel are as low as 1.25% with a scope of diluting further using our matched Negative Control - HD843, enabling assessment of minimal residual disease (MRD) typically replicating post-surgery and post-adjuvant treatment conditions. This reference material can also be used to validate companion diagnostic (CDx) tests which are used for tailoring treatments depending on the genetic make-up of the tumors for improved prognosis. The CRC ctDNA reference panel is a blend of highly characterized, cell line derived, clinically relevant mutations manufactured under ISO 9001:2015 and ISO 13485:2016.  

Technical data

Format: ctDNA

Genes covered: ABL1, ALK, ATK1, APC, BRAF, PIK3CA, KRAS, NRAS, PTEN, TP53

COSMICs: 10. See table below for full details

Allelic frequencies: 1.25% - 8.00%

Buffer: Tris-EDTA (10mM Tris-HCl, 1mM EDTA), pH 8.0

Product information

Fragment size: 160 bp

Unit size: 350 ng per vial

Concentration: 20 ng/µl

Verified mutations: 

General information

Storage: 4°C

Expiration: See all product shelf life information

Intended use: For assay developers, molecular diagnostic labs (Research use only)

Quality control

Fragmentation size: D1000 DNA ScreenTape assay

Allelic frequency: Droplet Digital™ PCR

Quantification: Qubit® dsDNA BR assay (Invitrogen)